Hudson Bay Capital Management LP Acquires 7,502 Shares of Intuitive Surgical, Inc. $ISRG

Hudson Bay Capital Management LP lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 65,132 shares of the medical equipment provider’s stock after purchasing an additional 7,502 shares during the period. Hudson Bay Capital Management LP’s holdings in Intuitive Surgical were worth $29,129,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ISRG. Brighton Jones LLC increased its position in Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after purchasing an additional 731 shares during the period. Sivia Capital Partners LLC lifted its position in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after purchasing an additional 34 shares during the period. Schnieders Capital Management LLC. boosted its stake in shares of Intuitive Surgical by 38.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after purchasing an additional 268 shares during the last quarter. Westover Capital Advisors LLC bought a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $206,000. Finally, Empowered Funds LLC grew its position in shares of Intuitive Surgical by 26.4% during the 2nd quarter. Empowered Funds LLC now owns 11,793 shares of the medical equipment provider’s stock worth $6,408,000 after buying an additional 2,465 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $477.73 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $603.88. The stock has a market cap of $169.66 billion, a P/E ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66. The firm has a 50 day moving average price of $507.10 and a 200 day moving average price of $512.85.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.26. The company had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period last year, the business posted $2.21 earnings per share. Analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insider Activity

In related news, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the sale, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. This trade represents a 28.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Fredrik Widman sold 133 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total value of $65,829.68. Following the transaction, the vice president owned 660 shares in the company, valued at approximately $326,673.60. This represents a 16.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,943 shares of company stock worth $17,279,568 in the last 90 days. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Argus cut their price objective on shares of Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Wall Street Zen cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. HSBC increased their price target on Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Sanford C. Bernstein raised their price target on Intuitive Surgical from $740.00 to $750.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Finally, Robert W. Baird dropped their price objective on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $614.95.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.